Investor litigation firm Kaskela Law announces that it is investigating Humana Inc. (NYSE: HUM) (“Humana”) on behalf of the company’s long-term investors.

Click here for additional information: https://kaskelalaw.com/case/humana/

Recently a federal securities fraud complaint was filed against Humana on behalf of certain investors who purchased shares of the company's stock between July 27, 2022 and October 1, 2024 (the “Wrongdoing Period”). According to the complaint, during the Wrongdoing Period, Humana and certain of its senior executive officers issued a series of materially false and misleading statements to investors about the company’s core Medicare Advantage business.

As further detailed in the complaint, the truth regarding Humana’s increased utilization began to emerge in June 2023, causing a series of stock price declines in the latter half of 2023 and during fiscal 2024.

The investigation seeks to determine whether the members of Humana’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Current Humana shareholders who purchased or acquired their HUM shares prior to July 1, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at abell@kaskelalaw.com, or online at:

https://kaskelalaw.com/case/humana/

ABOUT KASKELA LAW:

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis (i.e., the firm’s clients are never responsible for any out-of-pocket costs for legal representation). Since 2020, the firm has helped to recover over $500 million for investors. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com.

This communication may constitute attorney advertising in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260723453369/en/

The investigation seeks to determine whether the members of Humana's board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.